ConductScience.org, home

Paper36933320

Anti-TIGIT therapies for solid tumors: a systematic review.

Rousseau A and 2 others. ESMO Open, 2023. Cited by 136 papers, by iCite.

Cite this record

ConductScience Library. Anti-TIGIT therapies for solid tumors: a systematic review. Papers, record 36933320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36933320

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-TIGIT therapies for solid tumors: a systematic review.
PubMed
Journal
ESMO Open
PubMed
Year
2023
PubMed
Publication types
Systematic Review, Journal Article
PubMed
Citations, by iCite
136
iCite
Relative citation ratio, by iCite
10.3
iCite
Revised in PubMed
2026-01-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rousseau AA
2Parisi CC
3Barlesi FF

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Antibodies, Monoclonal
Nivolumab
Receptors, Immunologic

Source PubMed

Download CSV of topics

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130733837Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.Dis Markers2019https://conductscience.org/library/papers/30733837PubMed
221416464Vstm3 is a member of the CD28 family and an important modulator of T-cell function.Eur J Immunol2011https://conductscience.org/library/papers/21416464PubMed
331655605The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.J Immunother Cancer2019https://conductscience.org/library/papers/31655605PubMed
427718847Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med2016https://conductscience.org/library/papers/27718847PubMed
527546235Sex differences in immune responses.Nat Rev Immunol2016https://conductscience.org/library/papers/27546235PubMed
626413872TIGIT predominantly regulates the immune response via regulatory T cells.J Clin Invest2015https://conductscience.org/library/papers/26413872PubMed
734367161TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.Front Immunol2021https://conductscience.org/library/papers/34367161PubMed
828102259Elements of cancer immunity and the cancer-immune set point.Nature2017https://conductscience.org/library/papers/28102259PubMed
931954274Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).Int Immunopharmacol2020https://conductscience.org/library/papers/31954274PubMed
1032265229CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy.Cancer Immunol Res2020https://conductscience.org/library/papers/32265229PubMed
1116034094CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions.J Immunol2005https://conductscience.org/library/papers/16034094PubMed
1238206370Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.Cancer Chemother Pharmacol2024https://conductscience.org/library/papers/38206370PubMed
1328187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
1436289396Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.Sci Rep2022https://conductscience.org/library/papers/36289396PubMed
1535263569Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.Immunity2022https://conductscience.org/library/papers/35263569PubMed
1635522941PD-L1/TIGIT bispecific antibody showed survival advantage in animal model.Clin Transl Med2022https://conductscience.org/library/papers/35522941PubMed
1735273608An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.Front Immunol2022https://conductscience.org/library/papers/35273608PubMed
1819043418Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.Nat Immunol2009https://conductscience.org/library/papers/19043418PubMed
1934897277T cell receptor (TCR) signaling in health and disease.Signal Transduct Target Ther2021https://conductscience.org/library/papers/34897277PubMed
2034800678First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆.Ann Oncol2022https://conductscience.org/library/papers/34800678PubMed

See all 43 referencesDownload CSV of references

Cited by101

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.

PMIDTitleJournalYearIn PapersSource
42968166Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.J Transl Med2026https://conductscience.org/library/papers/42968166PubMed
42811017Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.Nat Commun2026https://conductscience.org/library/papers/42811017PubMed
42769891Resistance Mechanisms in Immunotherapy-Radiotherapy/Chemotherapy Combinations in Locally Advanced Head & Neck Squamous Cell Carcinoma.Oncol Res2026https://conductscience.org/library/papers/42769891PubMed
42768460Beyond PD-1: Expanding the Landscape of Immune Checkpoint Targets in Cancer Therapy.Curr Drug Targets2026https://conductscience.org/library/papers/42768460PubMed
42722716αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells.Cell Mol Immunol2026https://conductscience.org/library/papers/42722716PubMed
42654087The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.Pharmaceutics2026https://conductscience.org/library/papers/42654087PubMed
42574065Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.Clin Cancer Res2026https://conductscience.org/library/papers/42574065PubMed
42507968SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.J Clin Oncol2026https://conductscience.org/library/papers/42507968PubMed
42443153Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer.Cell Death Dis2026https://conductscience.org/library/papers/42443153PubMed
42353092Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression.Int J Mol Sci2026https://conductscience.org/library/papers/42353092PubMed
42352533The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42352533PubMed
42180871Integrated single-cell and bulk RNA sequencing reveals novel biomarkers of invasive adenocarcinoma subtypes in lung adenocarcinoma.Transl Cancer Res2026https://conductscience.org/library/papers/42180871PubMed
42161400CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42161400PubMed
42148118Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth.Front Immunol2026https://conductscience.org/library/papers/42148118PubMed
42097144HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.Cell Rep Med2026https://conductscience.org/library/papers/42097144PubMed
41883115Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies.J Gastroenterol Hepatol2026https://conductscience.org/library/papers/41883115PubMed
41876785Cellular landscape and diagnostic value of TROP2 in cerebrospinal fluid of lung adenocarcinoma leptomeningeal metastases.NPJ Precis Oncol2026https://conductscience.org/library/papers/41876785PubMed
41857153Prognostic impact of sarcopenia and blood biomarkers in advanced non-small cell lung cancer on first-line immune checkpoint inhibitors.Sci Rep2026https://conductscience.org/library/papers/41857153PubMed
41842954Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy.Inflamm Res2026https://conductscience.org/library/papers/41842954PubMed
41737188Proliferative double-negative T (DNT)-cell responses to PD-1 blockade therapy were positively correlated with good clinical outcomes in non-small cell lung cancer patients.Pak J Med Sci2026https://conductscience.org/library/papers/41737188PubMed

See all 101 cited byDownload CSV of cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADORA2A135PubTator's text mininghttps://conductscience.org/library/genes/135NCBI Gene
CD22610666PubTator's text mininghttps://conductscience.org/library/genes/10666NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CD9610225PubTator's text mininghttps://conductscience.org/library/genes/10225NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
HAVCR284868PubTator's text mininghttps://conductscience.org/library/genes/84868NCBI Gene
IKZF222807PubTator's text mininghttps://conductscience.org/library/genes/22807NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
NECTIN25819PubTator's text mininghttps://conductscience.org/library/genes/5819NCBI Gene
NRP18829PubTator's text mininghttps://conductscience.org/library/genes/8829NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
PVR5817PubTator's text mininghttps://conductscience.org/library/genes/5817NCBI Gene
PVRIG79037PubTator's text mininghttps://conductscience.org/library/genes/79037NCBI Gene
SEA6395PubTator's text mininghttps://conductscience.org/library/genes/6395NCBI Gene
TACSTD24070PubTator's text mininghttps://conductscience.org/library/genes/4070NCBI Gene
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene
TIGIT201633PubTator's text mininghttps://conductscience.org/library/genes/201633NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36933320

GET https://conductscience.org/api/papers/v1/36933320/references?page=2